 So thank you for sticking around in the late into the afternoon and giving me a chance to talk to you a little bit about Really sort of big picture stuff about some things that I've been thinking about with respect to early translational research at UCSF and some very preliminary Plans early plan your term plans for what what we hope to be able to to do in the in short order so As clay had just mentioned I Joined CTS I very recently Three months ago to be exact as a director of early translational research and before this I was at Genentech for Seven years in clinical development and in various different capacities and my most recent role was as the head of Infectious diseases cardiovascular metabolism and respiratory programs in in early clinical development And before that I was at UCSF for for a number of years as a clinical fellow in pulmonary and critical care a Research fellow and then on faculty and I also had directed the high-risk asthma clinic at San Francisco General And Why now some people have asked me why are you coming back and do you not like Roche or you know? So and it's actually not that it's not really so much a push, but it's really a pull I really think it's a very exciting time to be doing translational research especially in the in the setting of a place like UCSF for a variety of reasons UCSF I think by far Has some of the best science and some of the best scientists Around and those are obviously the two fundamental building blocks to be able to do good translational research You look around the campus and there's real intent and commitment to making translational research work better there's a Lot of energy being being expended into trying to figure out how to make translational research work better both here in academia and in the industry all around us and and Having good basic building blocks of good science and good scientists to work with is a great place to start you look around the campus And there's real intent and commitment you look at what's being done Through the evc's office with Decade of Human biology you look at what's being done at qb3 and and many other pockets around the campus People want to make this happen and then of course the leadership here with Jeff and the evc's office and sue has as the chancellor There's there's commitment External to UCSF it's it I think it's a really exciting time. There's it's dynamic lots of things changing very quickly there's full Acknowledgement and full recognition that things could be working better and Thing not that things have been working horribly, but a lot of things a lot There are a lot of variables that are rapidly evolving and therefore new gaps are sort of being identified and funding agencies by way of NIH and and regulatory agencies and and Industry from startups all the way through very large companies are acknowledging this and looking for new ways to Make this happen better and why because it's really important It's really a mandate because a great science that we have here should be translated to better help My goal and commitment is to really facilitate and enhance and accelerate early translational research and use at UCSF and The specific tactics for how that's going to happen is going to evolve over time I'm going to share one little bit with you a little bit later, but but really Spend a little bit more time just talking about the framework that I've been using to think about where the gaps are So what I've been doing I've been on a listening tour meeting with lots of folks around the campus some that are in this room to Understand what's been going on on campus with respect to T1 translational space and What works well what doesn't work well? What's missing? and and You know what what they wish they had that they don't have and then I'm also using that information to put together a business plan So the framework that I've been using to think about this is is is laid out over here. So Translational research, there's the early. There's late T1 T2 under T1 we're talking about science how science gets translated to invention Or discovery and and I'm using invention to be synonymous with that which is Which results in a patent? Recognizing that not all discoveries are patentable and not non patentable discoveries can also result in improvement of health and Then also there's the translation of this invention or discovery to a product and I'm using the word product to mean That entity drug device or diagnostic or software or whatever it is that can then be used to improve health out in the community and Then there's the other layer of bench to bedside bedside to bench and then how this gets then translated in the community and Really how then there's that feedback from community back to Bench and bedside to inform the science that occurs in Ideally and in reality That feedback Process is iterative I think one can argue that that feedback process could work better And we should be thinking about how that that Cross-fertilization could be facilitated better as well to to to create better science and then in terms of looking at Where does This work at the different ends of the translational spectrum occur Academia traditionally has been involved with work. That's fairly early bench at the bench some bedside and then science to invention and Sometimes a little bit beyond that Traditionally when there's an invention startup companies would Would come and and and get involved and then and then when those inventions have made a substantial progress To becoming a product larger companies would then take on that that program either by acquisition or by strategic partnership and then the other aspect is larger Farmers and traditionally and in the past historically has been really Doing a lot of investment into their own R&D pipeline So they've been putting a lot of resources into generating their own pipeline and doing their own research and development and I think all analysis would point to the the the Conclusion that that investment has not been nearly as fruitful as they had hoped and so they're looking for other other ways to fill their pipeline as well and What's happening now? I mean The number of there are a lot of variables at work Venture Venture resources are more scarce than they used to be started. It's harder to get startup companies Going and it's harder to keep them sustained Until a time when they're considered to be attractive to a larger strategic partner So there's that that gap between academia and startups is Increasing the gap between startup companies and large pharma and where in large pharma comes in It's also increasing for a variety of reasons one startup companies can't stay around quite as long as they used to because they don't have the Venture money that they used to and large pharma is Choosing to wait a little bit longer to invest in companies until sufficient risk has been mitigated in those companies So those gaps are being being increased So when we talk about a dynamic environment, this is sort of changing real-time and these gaps are Moving as we speak and so for so for so now large pharma is not is is Lot of large pharmas that that you've probably heard about in the press Are moving away from investing into their own R&D and Looking to academia and looking to get engaged more actively with the research that's going on in academia to Impart impart populate their R&D pipeline which From where we said I think is really an opportunity for a variety of reasons. They bring with that Potential resources not just monetary but capabilities things that we don't have in the university because we're not Primarily driven to do drug development. They bring their process development capabilities. They bring their manufacturing capabilities, so I think there are a lot of potential opportunities that we ought to be looking at in leveraging in this new dynamic environment so Looking at those three different levels Bench to bedside science to invention to product and then academia to industry, you know, they're they're They're their gaps from each of those steps so science to invention are How much science is really being left on the table without getting patents filed in this university and how do we Get access to that science so that whatever support it needs it can get to to move along Science with the potential to actually impact health and then invention to product. What keeps those those inventions? that that under go Getting patents filed from moving along to getting licenses done is it that That those capabilities are not Easily accessible to men. How do we how do we identify those to actually provide the necessary support to move that along? Bench to side and bedside to bench Do we have the infrastructures that we need to actually allow that bench to bedside bedside to bench to happen? And what are those things are those things that we have to build internally? Are those things that we can try to access and leverage from From the outside and I think these are all things That I've been thinking a lot about and I know lots of people here have been thinking about and working actively on and Then community to bench and then community bedside is the other Important piece and then academia to industry. We're in a dynamic time. It's it's gonna be interesting I think there were were open, but also the industry is also open to To really forming collaborations that make sense that are fit for purpose not one size fits all which I think has been more the approach historically And I think UCSF is a in a really unique unique position to really lead and influence and drive this Transformation that's occurring in that in the translational research space for a lot of reasons We have great science as we talked about and great scientists. We have this Institution that really has an amazing reputation, but also around us. We're probably in the most rich biotech innovation In the world area and the geographical area in the world So we have a lot of resources Around us that we ought to be tapping into that we need to leverage and I and I think that's really exciting There's a lot a lot of opportunity there so so What so I'm going to talk a little bit about? Specifically about one of our programs that was designed to address I have three minutes. Oh boy, okay And I need to go fast so To to address invention to product Stage the T1 cat trial and translational catalyst award meant to identify the best projects and then and then bring in missing pieces and help the the project along to a place where it's it's Then thought to be attractive to a some some some specific milestone and It's a phased award approach and I'm just going to share with you a case study of Bob Nussbaum Who apply for this program and the punchline is he actually didn't get the development award, but he did what what happened with his? his Program really beautifully illustrates the the strength of this program and that is he apply to test a commercial not commercial product the product and development at a at a startup company in a disease indication that Was different than what the company was working on so And what the company was planning on he really didn't have any idea so using a consultant that CTSI provided through the T1 catalyst program. He was then able to work out a collaborative Collaborative agreement with the company to be allowed to use the compound that they had in the disease indication that he's interested in We were then able to also provide them together the company and him and then a collaborator a Translational grant writer to apply for Michael J. Fox award together, and they've been invited to apply to do a full application now and We're in the final phases also of getting an MOU Memoranda of understanding written with this company so that should this Product and this should this invention ever become a product in This particular disease indication that UCSF would get something back for the investment that we made for for getting this program going so T1 catalyst award we did three cycles we Got some feedback that the pilot grants That were given through the program are thought to be very helpful Customized consulting service that was provided was very useful, and it can see that in the news palm case What we decided what we're working on now is thinking about how we can make those Those those aspects of the program that are thought to be most valuable more broadly available and in the process of thinking about How to broaden this t1 Translational catalyst award to a t1 translational catalyst program to include the award as it stands but also to have a separate freestanding customized consultation program and Then a pilot micro grants program and I the second and the third components of the consultation program and micro grants program are Designed to really be rapid turnover with minimal process Designed to help us identify the science to invention earlier programs a little bit better, so T1 translational or program is also being we're in the process of working on expanding the Expanding to have multiple tracks not just therapeutics, but diagnostics devices mHealth as well as orphan and rare diseases We're talking with many potential industry collaborators help to fund some of these different tracks so again instead of so we're we're It turns out that the t1 catalyst program is a a very interesting platform for the industry in Informing a potential collaboration with us, so we have been actively discussing That possibility with a number of different companies, so stay tuned and then so again I think it's one of the most important things that that are gonna help to to really extend the t1 Translational capability or capacity in academia is going to be innovative partnerships with Industry in a very innovative part partnerships with early-stage investors Founding foundations venture philanthropy and others and we are Exploring many of these avenues as we speak so please stay tuned there as well Your turn focus I'm going to be working on enhancing the t1 translational catalyst program and building and enhancing the Innovative partnerships and working closely with Eric from the ABC's office as well And then continuing to assess for opportunities and in figuring out ways to do Multidisciplinary cross-fertilization so important in the translational process from bench to bedside bedside to bench community bench and bedside and then and then also Really starting to think about what sort of t1 focused education both didactic and otherwise would be useful and then As we just finished talking about definition of success. How are we going to measure? Whether or not we're making an impact so How you can help me let me know For those of you who I haven't met with let me know when things if you know of things that are working well things that aren't working Well around the campus All years If you are aware of interesting and successful programs here or elsewhere that I to be aware of that we should evaluate Please let me know that too. If you have any project program or issue That CTSI or I in particular may be able to help with please call and contact me because I think that's part of that's going to be Part of my database and trying to figure out where where the gaps are on this university and then again other inputs are also appreciated Dynamic environment Means that we have to what you know We're gonna We're gonna need to do a Continual evaluation to identify and address gaps and this means gonna need to be agile And we're gonna need to be willing to take some small risks But most of I think we're really gonna need to work together because this is really a multi-disciplinary process And that's it. Thank you Thank you, June. So so June's just getting going here So it's already a lot of plans and a lot on your plate in a short period of time Any any questions from the group? We didn't really give you too much time to to talk about some of the exciting things that are sort of in the works but There are many We think and I wanted to just explain maybe before we transition if there are no questions that the this Why the T1 catalyst platform work seems to work so well So one of the one of the challenges in working with anybody outside the university is for them to know that they're interacting with the best folks Within UCSF right that these are the best projects that might meet their needs In otherwise our the environment. It's just too overwhelming. They can't understand what the heck's going on. They're just too many people From our perspective too when we've tried to do matchmaking Without any kind of assessment of projects and in that it's overwhelming to we get you know We say our doors open a lot of people come a lot of what they bring isn't worthwhile And then a lot of people who are doing the greatest stuff aren't motivated to bring their stuff in so what T1 catalyst does is it encourages People to submit their things for us to evaluate for us to prioritize them and then to present them to to buyers Basically, you know the potential partners whether they're foundation partners or industry part partners or whether it's our money That we're spending on it and that that seems to be working to help to to to bridge those gaps so sort of Take off on what was talked about earlier with profiles I'm wondering if there's any consideration Especially what clay just said on being able to drive profiles into that marketplace Maybe not being individuals even always but programmatic Programmatic profiles where we are the best asthma center in the country or we are the best and here's what we offer so that people can come into UCSF and understand what are what we're offering up so we don't have to necessarily always go out But we would be a place where people would come to if they have an interest in a disease area or in a in a in a biology area or in a In a group of people right now I think that's that's a great comment and there has been discussions and there's some thinking around not just saying This is the best asthma center, but really internally compiling a disease biology area that we have a continuum of expertise on from bait all the way from basic to basic to animal models to to clinical expertise and really compiling compiling those teams to to to be ready to engage quickly so Yes, and being able to being able to use I think profiles to a certain extent to to initiate that That that compilation of teams Yeah, it's a state stay tuned We're we're sort of selling that as part of a package in some of these relationships including the recent Pfizer one and then we'll try to deliver on their needs and through that will try to improve the product from their perspective Add a comment and question the first comment is we've we as a campus that we've done so much better at Talking about ourselves and what we're doing and you know our website is better or we have people who are ongoing around looking for Good work that people are doing we we mine good paper good publications and write about it in plain English And I think we should encourage the campus to continue to put resources in that because that'll help Elevate a lot of them, you know, it'll tell the stories and internally we'll learn and Externally people will learn about us as well because they will pick pick that information up and I think we've been doing so much better, which is Don't let that be one of the things we drop the ball on and my question is Jeff and you're You're you're pushed to us was to the decade of human biology and I wondered maybe I missed this But how is how are the two tied together and are there is there? Complete overlap with your goals in that and and the goals here to CTSI Well, we're in the process now of sort of our statement Reports to our office and so clay and Suzanne and others are talking all the time That this is an incredibly integrated process But what I don't want to lose in this and this is why I asked the question earlier on Is that in a sense the decade of human biology has a broader definition than what's being talked about here for translational research It's also talking about the human as a complex organism to do very basic research on It's it's human biology from the most basic research on and so we're gonna if anything make sure that The research community is involved as well. So it's not just a full overlapping Venn diagram Great. Well, I think we better move on it. Thank you very much, June